AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
-- 40 mg intravenous dose safe and active in stabilizing vision in wet AMD --
-- Conference Call/Webcast Scheduled for Today at 5:00 PM EST --
PLYMOUTH MEETING, Pa., March 1 /PRNewswire-FirstCall/ -- Genaera Corporation today announced data from a 24 week interim analysis of its largest Phase II trial, MSI-1256F-209 (Study 209), of EVIZON(TM) (squalamine lactate), under development for the treatment of "wet" age-related macular degeneration (AMD). At 24 weeks of therapy, the 40 mg dose of EVIZON was safe and well tolerated and stabilized vision in both the Study Eyes and the Fellow Affected Eyes of the majority of subjects.
In Study Eyes, ...